SOLNA, STOCKHOLM REGION, SWEDEN — April 22, 2026 — Barnik Invest today announced a strategic partnership with Mohammad Nahis Alanzi in Kuwait to support its expansion across the MENA region.
Through this collaboration, Barnik Invest enhances its regional platform to engage strategic stakeholders, structure cross-border partnerships, and advance the development and commercialization of its life science portfolio. Mr. Alanzi brings extensive senior-level experience across the healthcare value chain, including venture capital, pharmaceuticals, and medical education. As Executive Advisor, he will drive regional engagement and support the development of strategic partnerships aligned with Barnik’s portfolio.
Barnik Invest, together with its group companies, including Medicorent (CRO services) and StartUpPharma (commercialization and distribution)—provides integrated capabilities spanning regulatory, clinical development, and market access. This enables Barnik to support portfolio companies from early development through to commercialization and regional expansion.
This partnership establishes a structured platform to connect Nordic life science companies with partners across MENA, including healthcare providers, pharmaceutical companies, distributors, and institutional stakeholders—supporting both market entry and long-term value creation.
For more information, please contact;
Hamid Bakhshi, CEO
Telephone: +46738531165
E-mail: info@barnikinvest.com
About Barnik Invest Group
Barnik Invest Group is a leading 360 solution partner for Life Science companies in the Nordics. The company provides a comprehensive suite of services to support its portfolio companies, including capital, clinical development, expertise, and commercialization. Through its fully owned subsidiaries, Medicorent and StartUpPharma, Barnik Invest offers CRO services, outsourcing, recruitment, distribution, product development, and commercialization solutions. Barnik’s mission is to nurture promising life science companies from early clinical development to commercialization, enabling them to achieve positive cash flows or successful exits, and ultimately enhancing patient well-being and improving human health worldwide. For more information, visit www.barnikinvest.com.
